BYOOVIZ Q Code: Q5124

Drug & Product Overview

HCPCS Descriptor Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg

HCPCS Added Date April 1, 2022

Manufacturer Biogen

Route of Administration Intravitreal

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About BYOOVIZ

Byooviz is a medication aligned to the HCPCS Q Code: Q5124 for billing, pricing, and reimbursement purposes in the United States. It is an Ophthalmology drug administered via the intravitreal route and manufactured by Biogen.

According to CMS Drug Use Information: This medication is used to treat certain serious eye conditions (such as age-related macular degeneration, macular edema, diabetic retinopathy). It is used to help prevent decreased vision and blindness. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels. This monograph is about the following ranibizumab products: ranibizumab, ranibizumab-eqrn, ranibizumab-leyk, and ranibizumab-nuna.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
64406-0019-01	Byooviz	BIOGEN INC.	5	0.5 MG / 0.05 ML
82667-0018-05	Byooviz	Harrow Eye, LLC	5	0.5 MG / 0.05 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

BYOOVIZ Pricing & Reimbursement

Q5124 Private Payer Reimbursement

$61.24 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Ranibizumab Biosimilar Information:

BYOOVIZ Approval Date: September 17, 2021

Product Name	HCPCS Code	Active Ingredient	BLA Type
Lucentis	J2778	Ranibizumab	351(a) Originator Product
Byooviz	Q5124	Ranibizumab	351(k) Interchangeable
Cimerli	Q5128	Ranibizumab	351(k) Interchangeable
Nufymco	Q5168	Ranibizumab	351(k) Interchangeable
Ranluspec	N/A	Ranibizumab	351(k) Interchangeable

BYOOVIZ CPT Administration Codes

CPT Code	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

JW / JZ modifiers apply

CMS has identified Byooviz (Q5124) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

BYOOVIZ Medically Unlikely Edits (MUE)

The most billing units of Q5124 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.

Practitioner Office & Hospital Outpatient

10 units / day

= 1 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

BYOOVIZ Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Macular Edema Following Retinal Vein Occlusion (RVO) Myopic Choroidal Neovascularization (mCNV) Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Frequently Asked Questions

Is there an available Byooviz billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for BYOOVIZ.

Are there any available Byooviz patient assistance programs?

BYOOVIZ patient assistance information can be found through Biogen. Visit Here →

Where can I find Byooviz prescribing information?

BYOOVIZ prescribing information can be found at the link below: Visit Here →

Where can I find Byooviz side effect information?

Information regarding BYOOVIZ's side effects can be found at MedlinePlus Visit Here →

Does billing BYOOVIZ require JZ/JW wastage modifiers?

CMS has identified BYOOVIZ(Q5124) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.